Search

Displaying results 1781 - 1790 of 4588 in total
  1. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]

  2. Drug

    Technetium Tc-99m succimer

    go.drugbank.com/drugs/DB09436
    Approved

    It works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT). … [L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573]

  3. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

  4. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and ha...

  5. Drug

    Norepinephrine

    go.drugbank.com/drugs/DB00368
    ApprovedInvestigational

    Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter.

  6. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma

  7. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    [A32041] It was developed by MCPRF and FDA first approved in September 2012.

  8. Drug

    Frovocimab

    go.drugbank.com/drugs/DB15089
    Investigational

    Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).

  9. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  10. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).